Zhang et al. found that isorhamnetin was a dietary source of the PPARγ antagonist, which reduced body weight, ameliorated insulin resistance, and alleviated hepatic steatosis through the suppression of PPARγ transactivity, which was beneficial to obesity and hepatic steatosis [40]. Here, PPARG is linked to obesity disorder.